Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


loader
  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Follicular Lymphoma KOL Interview – US

    Follicular Lymphoma KOL Interview – US

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression, as well as unmet needs, are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, and mosunetuzumab.

    July 16, 2021
    Find out more
  • Human Papillomavirus (HPV) KOL Interview – Italy

    $599.00

    A European-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

    January 3, 2020
    Find out more
  • Biomedtracker Q3 2017 Outlook Report

    $599.00

    In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    August 2, 2017
    Find out more
  • Datamonitor-Acute-Myelogenous-Leukemia-KOL-Interview

    Acute Myelogenous Leukemia (AML) KOL Interview

    $599.00

    Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.

    August 19, 2016
    Find out more
  • Renal Cell Carcinoma KOL Interview – US, Southeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.

    May 13, 2020
    Find out more
  • MDS/AML KOL Interview

    $599.00

    Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

    April 9, 2015
    Find out more
  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more
  • Palbociclib for Breast Cancer

    $89.00

    Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

    February 1, 2014
    Find out more
  • GLP-1 Pulse Survey

    $599.00

    This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

    August 25, 2014
    Find out more
  • Selexipag for Pulmonary Arterial Hypertension

    $89.00

    Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.

    February 1, 2014
    Find out more
  • Dermatology KOL Interview

    $599.00

    BioMedTracker – Dermatology KOL Interview                                                                                                                           In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

    October 31, 2014
    Find out more
  • Major Depressive Disorder KOL Interview – UK

    $599.00

    A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.

    December 19, 2018
    Find out more
  • Datamonitor Schizophrenia KOL Interview

    $599.00

    On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

    February 10, 2016
    Find out more
  • Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

    April 28, 2021
    Find out more
  • Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

    $599.00

    An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

    November 12, 2018
    Find out more
Page 1 of 14
Page 1 of 14123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top